• Sales: € 1.79 billion, + 6 % in constant currency, + 4 % at actual rates
• EBIT: € 212 million, + 10 % in constant currency, + 8 % at actual rates
• Net income: € 46 million, + 21 % in constant currency, + 18 % at actual rates
• Strong sales and earnings growth at Fresenius Medical Care, in particular in North America and Europe
• Significant EBIT margin increase at Fresenius Kabi; return to positive sales growth in Germany accomplished
• Earnings improvement at Fresenius ProServe

Fresenius Medical Care to acquire Renal Care Group, Inc.

• Excellent strategic and geographic fit to Fresenius Medical Care's US operations
• On a combined basis more than 156,000 patients in over 2,000 dialysis clinics worldwide
• Anticipated neutral to slightly earnings accretive in 2006 and clearly accretive in 2007 and thereafter

Fresenius Medical Care to propose conversion of preference shares into ordinary shares in combination with a change of the company's legal form into a KGaA

• Strategic step that increases the financial flexibility of Fresenius Medical Care to exploit future growth opportunities
• Move toward a single share class will improve trading liquidity and the overall attractiveness of the ordinary shares
• Fresenius AG retains management control and continues to fully consolidate Fresenius Medical Care in its financial statements

First quarter 2005: Excellent start for Fresenius Group into fiscal year 2005

2005 Group outlook confirmed
Based on the excellent business performance in the first quarter, Fresenius confirms its positive 2005 full-year outlook before the impact of the Renal Care Group acquisition. Fresenius expects a constant-currency sales increase of 6 to 9 %. Net income is projected to grow by 15 to 20 % in constant currency. All business segments are expected to contribute to this increase.


Sustained sales growth
In the first quarter of 2005, group sales increased 6 % in constant currency. Organic growth contributed 4 % and acquisitions 3 % to this increase. Currency translation effects had a -2 % and disinvestments a -1 % effect on sales. At actual rates, sales were € 1,787 million, an increase of 4 % (Q1 2004: € 1,720 million).

Excellent constant-currency sales growth was achieved in North America (+8 %), in Latin America (+22 %) and in Africa (+53 %). Asia-Pacific had excellent sales growth for Fresenius Kabi offset by Fresenius ProServe's low project volume in this region compared to 2004.



Sales contribution of the three business segments:



Strong earnings growth
Fresenius achieved excellent growth rates in earnings: EBITDA rose 8 % in constant currency and 6 % at actual rates to € 284 million (Q1 2004: € 269 million). EBIT rose 10 % in constant currency and 8 % at actual rates to € 212 million (Q1 2004: € 197 million). The EBIT margin further improved to 11.9 % in the first quarter 2005 (Q1 2004: 11.5 %).

Net interest expense improved to € -47 million (Q1 2004: € -52 million) due to a lower debt level compared to the first quarter of 2004 in combination with lower interest rates and minor currency translation effects.

The tax rate for the first quarter of 2005 was 39.4 % (Q1 2004: 40.0 %), in line with the full-year expectation of 39 to 40 %.

Minority interest increased to € 54 million (Q1 2004: € 48 million). Minority share-holders in Fresenius Medical Care accounted for 96 % of minority interests.

Net income rose 21 % in constant currency and 18 % at actual rates to € 46 million (Q1 2004: € 39 million). EBIT growth at Fresenius Medical Care and Fresenius Kabi as well as lower interest expenses were key drivers for this increase.

Earnings per ordinary share were € 1.11 (Q1 2004: € 0.94). Earnings per preference share were € 1.12 (Q1 2004: € 0.95). EPS increased by 18 % for both share classes.


Investments on target
Group investments in the first quarter of 2005 were € 229 million. As expected, this was a significant increase from the same period of the previous year (Q1 2004: € 89 million). € 48 million was spent for property, plant and equipment and intangible as-sets (Q1 2004: € 48 million) and € 181 million for acquisitions (Q1 2004: € 41 million).


Solid cash flow performance
Operating cash flow decreased 8 % to € 168 million (Q1 2004: € 182 million) despite the excellent quarterly earnings. This was mainly due to higher income tax payments of Fresenius Medical Care in North America. Free cash flow before acquisitions was € 126 million (Q1 2005: € 136 million). Free cash flow after acquisitions and dividends was € -9 million (Q1 2004: € 98 million).


Solid balance sheet structure
Total assets increased 5 % to € 8,625 million (December 31, 2004: € 8,188 million). In constant currency, total assets grew by 3 %. Current assets increased 7 % to € 2,939 million, mainly due to acquisitions (December 31, 2004: € 2,755 million). In constant currency current assets rose 5 %.

Group debt rose 3 % to € 2,813 million as of March 31, 2005, primarily as a result of acquisitions. (December 31, 2004: € 2,735 million). In constant currency the increase was 1 %.

Based on the positive EBITDA development, the ratio net debt/EBITDA remained almost unchanged at 2.3 as of March 31, 2005 despite the increased debt level (December 31, 2004: 2.2).

Shareholders' equity including minority interests rose 7 % to € 3,565 million compared to € 3,347 million on December 31, 2004. The equity ratio including minority interest improved to 41.3 % (December 31, 2004: 40.9 %).


Employee numbers continue to grow
As of March 31, 2005, the Group had 69,874 employees worldwide, an increase of 2 % (December 31, 2004: 68,494).


Fresenius Biotech
Fresenius Biotech develops innovative therapies with trifunctional antibodies for the treatment of cancer as well as cell therapies for the treatment of the immune system. In the field of polyclonal antibodies, Fresenius Biotech has successfully marketed ATG-Fresenius S for many years. ATG-Fresenius S is an immunosuppressive agent used to suppress graft rejection following an organ transplantation.

In the field of cancer treatment, the final results of two Phase I studies will be presented on May 17, 2005 during the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO):

• the use of the antibody removab® in peritoneal carcinomatosis and
• the use of the antibody rexomun® in breast cancer.

A Phase II study for the treatment of breast cancer and a phase II study for the treatment of gastric cancer are now in preparation following the encouraging results. The studies are scheduled to commence at the end of 2005.

For 2005, Fresenius Biotech continues to expect an EBIT in the range of € -35 to € -40 million, largely due to the expanded clinical study program.


The Business Segments

Fresenius Medical Care
Fresenius Medical Care is the world's leading provider of products and services for patients with chronic kidney failure. As of March 31, 2005, Fresenius Medical Care treated about 125,900 patients (+5 %) in 1,630 dialysis clinics (+4 %).

• Excellent growth in sales and earnings continued
• Successful business performance in North America and Europe
• 2005 outlook confirmed

Fresenius Medical Care achieved excellent sales growth of 10 % to US$ 1,609 million in the first quarter of 2005 (Q1 2004: US$ 1,459 million). In constant currency, sales rose 9 %. Organic sales growth was 7 %.

In North America Fresenius Medical Care increased revenues by 9 % to US$ 1,088 million (Q1 2004: US$ 1,003 million). Sales outside North America (the "Interna-tional" segment) rose 14 % (in constant currency: 8 %) to US$ 521 million (Q1 2004: US$ 456 million) mainly due to the very positive business performance in Europe.

Sales in dialysis care rose 10 % to US$ 1,162 million (Q1 2004: US$ 1,058 million). In the first quarter of 2005, Fresenius Medical Care performed about 4.72 million
dialysis treatments, an increase of 3 %. This includes 3.25 million treatments in North America (+3 %) and 1.47 million outside North America (+5 %). In dialysis products, Fresenius Medical Care achieved sales growth of 11 % to US$ 447 million (Q1 2004: US$ 401 million).

Fresenius Medical Care's EBIT increased by 11 % to US$ 220 million (Q1 2004: US$ 198 million), the EBIT margin was 13.7 %. Net income increased 18 % to US$ 107 million in the first quarter of 2005.

For the year 2005, Fresenius Medical Care confirms its outlook before the impact of the Renal Care Group acquisition. The company expects a revenue growth at constant currency between 6 and 9 % and net income growth in the low double-digit range.

For more information, see Fresenius Medical Care Investor News at www.fmc-ag.com.

Fresenius Kabi
Fresenius Kabi offers infusion therapies and clinical nutrition for seriously and chronically ill patients in the hospital and out-patient environment. The company is also a leading provider of transfusion technology products.

• Profitability significantly increased; EBIT margin of 13.1 % achieved
• Positive sales performance in Germany
• 2005 outlook confirmed

The acquisition of the Portuguese company Labesfal announced in early January was successfully closed in the first quarter of 2005. Labesfal manufactures and markets intravenously administered drugs (I.V. drugs). The company is consolidated in the financial statements of Fresenius Kabi as of January 1, 2005.

Sales at Fresenius Kabi rose 10 % in the first quarter of 2005 to € 398 million (Q1 2004: € 362 million). The company achieved good organic growth of 5 %. Acquisitions, mainly Labesfal, contributed 5 % to sales. Currency translation effects increased sales by 1 %, divestitures had a -1 % effect.

The development in the German market was positive. Fresenius Kabi was able to increase sales by 2 % after a decrease of 5 % in the first quarter 2004 which was a result of health care reform. Sales in the rest of Europe rose 12 %, mainly due to acquisitions. The Asian-Pacific region posted strong organic growth of 14 %.

Earnings developed positively in the first quarter of 2005. EBIT rose 27 % to € 52 million (Q1 2004: € 41 million). The EBIT margin was 13.1 % in the first quarter of 2005, an increase of 180 basis points compared to the first quarter of 2004 (11.3 %) and 90 basis points compared to the fourth quarter of 2004 (12.2 %).

Fresenius Kabi confirms its outlook for 2005. Including the Labesfal acquisition, constant-currency sales are expected to increase by about 10 % and the EBIT margin is projected to increase to >13 %.

Fresenius ProServe
Fresenius ProServe offers services for international health care systems, including hospital management, the planning and construction of hospitals and pharmaceutical and medical-technical production plants.

• Earnings improvement accomplished
• Decline in sales due to restrained order situation in project business
• 2005 outlook confirmed

Fresenius ProServe achieved sales in the first quarter of 2005 of € 171 million (Q1 2004: € 199 million). On a comparable basis (excluding the nursing home business sold in 2004 and the discontinued international hospital management business), the sales decrease would have been 10 %.This decrease mainly resulted from the delayed closing of projects in the hospital engineering and services business (VAMED). Continued investment caution of the pharmaceutical industry led to lower sales in pharmaceutical engineering and services (Pharmaplan). Sales in the hospital management business met expectations (Wittgensteiner Kliniken).

In the first quarter of 2005, Fresenius ProServe increased EBIT to € 3 million (Q1 2004: € 1 million; before one-time expenses: € 2 million).

Order intake in the first quarter of 2005 was € 47 million (Q1 2004: € 70 million). For the full year 2005, Fresenius ProServe expects order intake to increase compared to 2004. The bulk of new orders is expected to be acquired in the third and fourth quarters of 2005.

Fresenius ProServe confirms its outlook for 2005 and expects an EBIT between € 20 and € 25 million. Organic sales growth is expected to be in the range of 5 to 8 %.

Fresenius Medical Care to acquire Renal Care Group, Inc.
Fresenius Medical Care today announced that it has entered into a definitive agreement to acquire Renal Care Group, Inc., (NYSE: RCI), Nashville, Tennessee, for a price of US$ 48.00 per share in cash. The total net consideration for the acquisition of all outstanding shares of Renal Care Group is US$ 3.5 billion, which will be all-debt financed. The acquisition is anticipated to be neutral to slightly accretive to earnings in 2006 and clearly accretive to earnings in 2007 and thereafter.

Renal Care Group is a fast-growing, highly profitable dialysis service provider that will be an attractive complement to Fresenius Medical Care's US business. In 2004, Renal Care Group's revenue was approx. US$ 1.35 billion with an EBIT of US$ 254 million, net income was US$ 122 million. As of March 31, 2005, Renal Care Group owned more than 425 dialysis clinics and served over 30,400 patients. Through the combination with Renal Care Group, Fresenius Medical Care will be well positioned to create additional growth potential for its dialysis product business and will provide opportunities to successfully leverage its cost leadership position in dialysis products and services.

Fresenius Medical Care plans to finance the acquisition primarily through an extension of its senior credit agreement. The existing US$ 1.2 billion credit agreement will be replaced by a US$ 5.0 billion senior credit facility. Financing commitments have been received from Bank of America and Deutsche Bank, and are subject to customary conditions.

The transaction is subject to the approval of Renal Care Group's shareholders and other customary closing conditions, including the expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act.

For further details please see separate Investor News of Fresenius Medical Care at www.fmc.ag.com.

Fresenius Medical Care to propose conversion of preference shares into ordinary shares in combination with a change of the company's legal form into a KGaA
Fresenius Medical Care further announced its intention to offer the holders of the company's approx. 26.4 million preference shares the opportunity to convert these into ordinary shares. The preference shareholders who participate in this program pay a "premium" of € 12.25 per share for the conversion. Furthermore, the company will ask its ordinary shareholders to approve a change of the legal form from an "Aktiengesellschaft" (AG) to a "Kommanditgesellschaft auf Aktien" (KGaA).

As part of the transformation of legal form, a subsidiary of Fresenius AG in the legal form of a "Aktiengesellschaft" (stock corporation under German law) will be established as general partner of the Fresenius Medical Care AG & Co. KGaA. The Management Board of the general partner – which will be identical with the current Management Board of Fresenius Medical Care – will assume the management of Fresenius Medical Care. As long as Fresenius AG maintains ownership of more than 25 % of the share capital of the company, Fresenius AG will retain its current controlling position and fully consolidate the company in its financial statements.

The proposed change in the legal form of Fresenius Medical Care will allow to continue the high standards of corporate governance and transparency as today.

For further details please see separate Investor News of Fresenius Medical Care at www.fmc-ag.com

Fresenius Biotech successfully completed two Phase I studies evaluating trifunctional antibodies in the treatment of breast cancer and peritoneal carcinomatosis. The results of these studies were presented by investigators from the participating universities at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida.

Encouraging results were achieved with the trifunctional antibody rexomun^® (WHO INN: ertumaxomab), which was evaluated in a clinical trial for the first time. In this multi-center Phase I study including patients with metastastic breast cancer, rexomun^® (ertumaxomab) proved to be safe and tolerable. Seventeen patients were involved in the study and received three intravenous doses of the antibody within a two-week period. The maximum tolerated doses for the first, second and third application were found at 10, 100 and 100 micrograms. Side effects were mild to moderate and transient with fever, chills, headache and nausea being the most common. In five out of 15 evaluable patients the tumor responded to the treatment leading to stable disease or remission. One patient had a complete remission that lasted for 7 months, two patients had a partial remission and two patients had stable disease. One patient with partial remission and two patients with stable disease received concomitant or subsequent hormone therapy. "These data strongly encourage us to proceed into phase II," said Dr. Thomas Gottwald, President of Fresenius Biotech. A Phase II study evaluating the efficacy of rexomun^® (ertumaxomab) in breast cancer is in preparation and will start by the end of 2005.

In the second multi-center Phase I study presented at the ASCO convention, the trifunctional antibody removab^® (INN: catumaxomab) proved to be safe and tolerable in the treatment of peritoneal carcinomatosis. A total of 17 patients were included. In 16 patients the peritoneal carcinomatosis was caused by cancer of the stomach or the colon. In one patient, the primary tumor could not be located. Four increasing doses of removab^® (catumaxomab) were injected into the peritoneal cavity of the patients over a 10-day period. The maximum tolerated doses were found at 10, 20, 50 and 200 micrograms in the first, second, third and fourth infusion. Side effects were mild to moderate and transient with nausea, abdominal pain and fever being the most common. Irrigation of the peritoneal cavity was possible in eight patients before and after the treatment to determine the effect on the number of detected tumor cells, which decreased in seven out of these eight patients after treatment.

The average life expectancy of patients with peritoneal carcinomatosis normally ranges from three to six months. To date, 14 months after the start of the study, 7 out of 17 patients are still alive. Follow up showed survival of about 9 months after the start of treatment. Complete remission was achieved in one patient which continues after 14 months. "Again, like in the previous study on the trial on malignant ascites due to ovarian cancer, we have observed first signs of efficacy at an early stage of the clinical development," explained Dr. Thomas Gottwald. A pilot study is now evaluating the best mode of application of removab^® (catumaxomab) in gastric cancer. A Phase II study on gastric cancer is expected to start by the end of 2005.

The trifunctional antibody removab^® (catumaxumab) is also currently being evaluated in a Phase IIa trial in the treatment of ovarian cancer and in a Phase II/III pivotal trial in the treatment of malignant ascites. The results of these studies should be available during 2006.

The antibodies rexomun^® (ertumaxomab) and removab^® (catumaxomab) were developed and produced by Fresenius Biotech's partner TRION Pharma, a Munich-based biotech company. These novel antibodies have a unique mode of action. Trifunctional antibodies selectively bring together cancer cells and two different immuno-competent cell types thus prompting the destruction of the tumor cells. In addition, trial results indicate that these antibodies prime the immune system with the potential for long lasting immunity against the tumor.

Clinical studies: Phase I studies evaluate dose, safety and tolerability while Phase II clinical trials investigate the efficacy of new drugs.

INN: International Nonproprietary Name; Each INN is selected by the WHO, is a unique name that is globally recognized and is public property.

Fresenius AG today announced that Standard & Poor's and Moody's will change their credit ratings for the Company by one notch. Standard & Poor's plans to lower its rating from "BB+" to "BB" with a negative outlook upon completion of the Renal Care Group acquisition by Fresenius Medical Care. Moody's lowered its rating from "Ba1" to "Ba2" in anticipation of the Renal Care Group acquisition. The outlook is stable.

Stephan Sturm, Chief Financial Officer, commented: "This is an expected downgrade given the decision to fully debt-finance the acquisition of Renal Care Group. On the other hand, the acquisition sustainably strengthens Fresenius Medical Care's position in the global dialysis market. We have a proven ability to considerably reduce debt from solid cash flows and are therefore confident to meet our financial goals."

• Sales: € 3.70 billion, + 6 % in constant currency, + 4 % at actual rates
• EBIT: € 453 million, + 12 % in constant currency, + 10 % at actual rates
• Net incombe: € 101 million, + 28 % in constant currency, + 26 % at actual rates
• Strong sales and earnings growth at Fresenius Medical Care; driven by continued gains in North America and Europe
• Fresenius Kabi achieves new record in EBIT margin; very good sales development in all regions
• Fresenius ProServe improves earnings and achieves good order intake

2005 Group outlook raised
Based on these excellent results Fresenius raises its full-year outlook (before the acquisition of Renal Care Group by Fresenius Medical Care) and now expects net income growth of 20 to 25 % in constant currency. Previously, the Company expected 15 to 20 % net income growth. The projection for sales growth in constant currency remains at 6 to 9 %. All business segments are expected to achieve sales and earnings growth.

Sustained sales growth
In the first half of 2005, Group sales increased 6 % in constant currency. Organic growth contributed 5 % and acquisitions 2 % to this increase. Currency translation had a -2 % and divestments a -1 % effect on sales. Sales were € 3,702 million, an increase of 4 % at actual rates (H1 2004: € 3,553 million).

Strong constant-currency sales growth was achieved in North America (+7 %), in Latin America (+19 %) and in Africa (+44 %). In Asia-Pacific, Fresenius Kabi achieved an excellent sales growth. The lower project volume at Fresenius ProServe primarily impacted the sales development in this region.



Sales contribution of the three business segments:



Strong earnings growth
EBITDA increased 9 % in constant currency and 7 % at actual rates to € 604 million (H1 2004: € 564 million). Group EBIT rose 12 % in constant currency and 10 % at actual rates to € 453 million (H1 2004: € 412 million). The Group EBIT margin further improved to 12.2 % in the first half of 2005 (H1 2004: 11.6 %).

Group net interest expense was € -97 million in the first half of 2005 (H1 2004: € -104 million). This improvement was mainly the result of a lower debt level compared to the first half of 2004 in combination with lower interest rates and currency translation effects. The tax rate for the first half of 2005 was 39.3 % (H1 2004: 40.6 %), in line with the full-year expectation of 39 to 40 %.

Minority interest increased to € 115 million (H1 2004: € 103 million) mainly due to the strong earnings development of Fresenius Medical Care, which accounts for 96 % of minority interest.

Group net income grew strongly by 28 % in constant currency and 26 % at actual rates to € 101 million (H1 2004: € 80 million). Excellent operating results of Fresenius Medical Care and Fresenius Kabi, lower interest expenses and a slightly lower tax rate contributed to this increase.

Earnings per ordinary share were € 2.46 (H1 2004: € 1.95). Earnings per preference share were € 2.48 (H1 2004: € 1.97). EPS increased 26 % for both share classes.

Investments considerably increased
In the first half of 2005, Group investments doubled to € 342 million (H1 2004: €172 million). This significant increase was mainly driven by acquisitions at Fresenius Kabi. € 115 million was spent for property, plant and equipment and intangible assets (H1 2004: € 111 million) and € 227 million for acquisitions (H1 2004: € 61 million).

Solid cash flow performance
Operating cash flow was slightly lower than in the previous year at € 329 million (H1 2004: € 340 million) despite the excellent earnings development. This was mainly due to higher income tax payments of Fresenius Medical Care in North America. Free cash flow before acquisitions and dividends was € 224 million (H1 2004: € 239 million). Free cash flow after acquisitions (€ 182 million) and dividends (€ 127 million) was € -85 million (H1 2004: € 67 million).

Solid balance sheet structure
Total assets increased 10 % to € 9,045 million (December 31, 2004: € 8,188 million). In constant currency, total assets grew 3 %. Current assets increased 12 % to € 3,090 million (December 31, 2004: € 2,755 million). In constant currency, current assets grew 6 %. This increase was driven by acquisitions and growth of operations.

Group debt rose 9 % to € 2,993 million as of June 30, 2005 (December 31, 2004: € 2,735 million). In constant currency, debt grew 5 % and was driven by acquisitions.

The net debt/EBITDA ratio was 2.4 as of June 30, 2005 (December 31, 2004: 2.2). The positive EBITDA increase partially offset the higher debt level.

Shareholders' equity including minority interest rose 11 % to € 3,721 million compared to € 3,347 million on December 31, 2004. The equity ratio including minority interest improved to 41.1 % (December 31, 2004: 40.9 %).

Employee numbers continue to grow
As of June 30, 2005, the Group had 71,109 employees worldwide, an increase of 4 % (December 31, 2004: 68,494).

Fresenius Biotech
Fresenius Biotech develops innovative therapies with trifunctional antibodies for the treatment of cancer as well as cell therapies for the treatment of the immune system. In the field of polyclonal antibodies, Fresenius Biotech has successfully marketed ATG-Fresenius S for many years. ATG-Fresenius S is an immunosuppressive agent used to prevent and treat graft rejection following organ transplantation.

In the field of antibody therapies, two phase II studies are in preparation to investigate the treatment of gastric cancer and breast cancer following positive results from two phase I studies for the treatment of peritoneal carcinomatosis and breast cancer. Current studies for malignant ascites, malignant pleural effusion and ovarian cancer are continuing according to plan.

For 2005, Fresenius Biotech continues to expect an EBIT in the range of € -35 to € -40 million, largely due to the expanded clinical study program.

The Business Segments

Fresenius Medical Care
Fresenius Medical Care is the world's leading provider of products and services for patients with chronic kidney failure. As of June 30 2005, Fresenius Medical Care was serving approximately 128,200 patients (+4 %) in 1,645 dialysis clinics (+3 %).

• Strong sales and earnings growth continued
• North America and Europe once again key sales and earnings drivers
• 2005 net income outlook raised

In the first half of 2005, Fresenius Medical Care achieved sales growth of 9 % to US$ 3,283 million (H1 2004: US$ 3,011 million). In constant currency, sales rose 7 %. Organic growth was 6 %.

In North America Fresenius Medical Care achieved a strong sales increase of 7 % to US$ 2,215 million (H1 2004: US$ 2,063 million). Sales outside North America ("International") rose 13 % to US$ 1,068 million (H1 2004: US$ 948 million) mainly because of the very good development of the European business.

Sales in dialysis care increased 8 % to US$ 2,363 million (H1 2004: US$ 2,185 million). In the first half of 2005, Fresenius Medical Care delivered approximately 9.6 million dialysis treatments, an increase of 4 % over the same period in the previous year. North America accounted for 6.6 million treatments (+3 %) and the International segment for 3.0 million treatments (+5 %). Fresenius Medical Care achieved sales growth in dialysis products of 11 % to US$ 920 million (H1 2004: US$ 826 million).

EBIT rose 11 % to US$ 458 million (H1 2004: US$ 411 million) and the EBIT margin was 14.0 % (H1 2004: 13.6 %). Net income at Fresenius Medical Care grew to US$ 223 million in the first half of 2005, an increase of 17 %.

Based on its strong performance in the first half of 2005, Fresenius Medical Care now expects net income growth to be between 12 and 15 %. Previously, the company anticipated net income growth for 2005 to be in the low double-digit range. This guidance does not take into effect the impact of the Renal Care Group acquisition or the expected one-time costs of around US$ 10 million for the full year 2005 in connection with the transformation of Fresenius Medical Care's legal form, or the conversion of the preference shares into ordinary shares. Top-line revenue growth at constant currency should remain between 6 and 9%.

For further information, please see Fresenius Medical Care's Press release.

Fresenius Kabi
Fresenius Kabi offers infusion therapies and clinical nutrition for seriously and chronically ill patients in the hospital and out-patient environments. The company is also a leading provider of transfusion technology products.

• Earnings target exceeded: new record EBIT margin of 13.8 % in the second quarter of 2005
• Excellent organic growth of 6 % in the first half of 2005
• 2005 earnings outlook raised

In the first half of 2005, sales at Fresenius Kabi rose 11 % to € 818 million (H1 2004: € 738 million). The company achieved an excellent organic growth of 6 %. Acquisitions, primarily the Portuguese company Labesfal, contributed 5 % to sales. Currency translation added 1 % to sales growth. Divestments had a -1 % effect on sales.

Sales in Germany rose 2 %. Sales in Europe (excluding Germany) increased 13 %. Acquisitions contributed significantly to this growth. Fresenius Kabi continued to grow at double-digit rates outside of Europe: The Asia-Pacific region showed strong organic growth with an increase of 16 % and Latin America posted organic sales growth of 13 %.

Fresenius Kabi significantly increased earnings. EBIT rose 29 % in the first half of 2005 to € 110 million (H1 2004: € 85 million). The EBIT margin was 13.4 %, an increase of 190 basis points compared to the first half of 2004 (11.5 %). Compared to the first quarter of 2005, the Q2-EBIT margin improved by 70 basis points to 13.8 %.

Fresenius Kabi clearly exceeded the projected full-year EBIT margin target of >13.0 % in the first half of 2005. Therefore, the company raises its full-year EBIT margin outlook to >13.5 %. Constant-currency sales growth should remain at about 10 %.

Fresenius ProServe
Fresenius ProServe offers services for the international health care sector including hospital management and hospital planning and construction as well as planning and construction of pharmaceutical and medical-technical production sites.

• Further improvement in earnings
• Good order intake
• Sales below previous year due to project delays

In the first half of 2005, Fresenius ProServe achieved sales of € 350 million (H1 2004: € 383 million). On a comparable basis (excluding the nursing home business sold in 2004 and the discontinued international hospital management business), the sales decrease would have been 4 %. This decrease resulted from delayed closing of projects in the hospital engineering and services business (VAMED). In addition, the ongoing investment caution in the pharmaceutical industry led to lower sales in pharmaceutical engineering and services (Pharmaplan). An increase in sales of 3 % was achieved in the hospital management business (Wittgensteiner Kliniken).

EBIT increased to € 7 million in the first half of 2005 despite lower sales (H1 2004: € 0 million; before one-time charges: € 6 million). On a comparable basis, this is an increase of 17 %.

Order intake developed very positively in the second quarter and reached € 109 million. Order intake in the first half of 2005 increased 15 % to € 156 million (H1 2004: € 136 million). Order backlog in the first half of 2005 increased 14 % to € 382 million (December 31, 2004: € 335 million). Based on this development and additional contracts expected to be signed in the third and fourth quarters of 2005, Fresenius ProServe expects improved sales in the second half of 2005.

Fresenius ProServe confirms its full-year outlook for 2005 and expects an EBIT of € 20 to € 25 million and an organic sales growth of 5 to 8 %.


Live video webcast
As part of the earnings announcement for the first half of 2005, an analyst conference will be held at the Fresenius headquarters in Bad Homburg on August 4, 2005 at 1:30 p.m. CEDT (7.30 a.m. EDT). The analyst conference will be broadcast live over the Internet at www.fresenius-ag.com / Investor Relations / Presentations. Following the meeting, a recording of the conference will be available as video-on-demand.

Quarterly report
The full first-half and second-quarter report will be available on the Internet by August 15, 2005 at www.fresenius-ag.com / Investor Relations / Publications.

Bad Homburg, Germany - October 10, 2005 - Fresenius Medical Care AG ("the Company") (Frankfurt Stock Exchange: FME, FME3) (NYSE: FMS, FMS-p), the world's largest provider of Dialysis Products and Services, today announced that the Company has been named in some civil actions by a small number of shareholders contesting the resolutions of the Extraordinary General Meeting ("EGM"). The EGM was held August 30, 2005 to transform the Company's legal form into a partnership limited by shares ("KGaA") and to convert the preference shares into ordinary shares to move to one share class. The Company believes that these actions are without merit and it will defend vigorously the resolutions adopted by the EGM in an appropriate way.

The transformation of the Company's legal form and the conversion of the preference shares were approved by an overwhelming majority of common and preference shareholders at the EGM. The transformation was approved by nearly 91% of the represented ordinary share capital, and the conversion was approved by nearly 94% of the represented ordinary share capital. At the Separate Meeting of Preference Shareholders, which was held immediately following the EGM, the preference share conversion proposal was approved by nearly 85% of the represented preference share capital. Moreover, broad shareholder support for the resolutions is also evidenced by the strong share price development since the announcement in May 2005.

As a result of the acceptance of these capital structure changes by the majority of the shareholders and the financial community, Fresenius Medical Care will continue its preparation to accomplish these value-enhancing transactions with determination.

• Acquisition of HELIOS Kliniken builds Fresenius ProServe's hospital management business
• Acquisition of Clinico to develop Fresenius Kabi's medical devices business
• Committed financing
• Excellent financial results in the 1st-3rd quarter of 2005 (preliminary); 2005 Group outlook – earnings guidance raised

Acquisition of HELIOS Kliniken GmbH, a leading hospital operator in Germany
Fresenius has entered into an agreement to acquire HELIOS Kliniken GmbH, Fulda, Germany. Through the acquisition, Fresenius creates an excellent platform for further growth in the German acute care market. HELIOS is recognized for having medical quality standards of the highest level in the industry. With expected sales of approx. € 1.2 billion in 2005 the company ranks among the largest and financially most successful private hospital chains in Germany. The acquisition of HELIOS will establish Fresenius ProServe as one of the leading private hospital operators in Germany and create a strong third business segment within Fresenius Group.

„The hospital management business in Germany has been our clear focus following the streamlining of Fresenius ProServe's operations in 2003 and 2004. The acquisition of one of the most successful German hospital operators is an unique opportunity to strengthen our position in acute care hospitals. Building on this strong position, we will capitalize on the excellent growth potential of the ongoing privatization process in the German hospital market. HELIOS is an extremely well-managed company and is, just like Fresenius, strongly committed to deliver best-in-class medical treatment," commented Dr. Ulf M. Schneider, Chairman of the Management Board of Fresenius AG.

HELIOS Kliniken GmbH is one of the leading private German hospital operators in terms of revenue growth and profitability. Since 2002, the company posted a compounded annual growth rate of 28 % in sales. In 2004, HELIOS achieved revenues of € 1,161 million, operating income of € 95 million and net income of € 66 million. The company owns 24 hospitals with a total capacity of approx. 9,300 beds. HELIOS is the only hospital chain in Germany that operates four maximum-care hospitals with more than 1,000 beds each. The company has approx. 18,000 employees and performs about 330,000 inpatient and about 700,000 outpatient treatments annually.

HELIOS enjoys an excellent reputation with medical experts and patients. The company implemented a comprehensive medical quality management system and is the first German hospital chain that sets quantitative medical targets. The Annual report as well as the quality and intellectual capital reports document HELIOS's achievements and targets with outstanding transparency. HELIOS's experienced and acquisition-proven management team will continue to manage the company. All members of the HELIOS Management continue to be shareholders in the company.

"Our proven medical know-how and partnership network management is the basis for our leading position in medical quality standards. With Fresenius, we will further strengthen this position. We are well prepared for further growth in the highly dynamic German hospital market for acute care, even for ambitious privatization projects," commented Ralf Michels, Managing Director of HELIOS Kliniken GmbH.

In the future, the hospitals of HELIOS and the Fresenius hospitals of the Wittgensteiner Group will operate under the leadership and brand of HELIOS. Both companies are highly complementary in terms of geographical fit and medical focus. The combined business will include 55 clinics with 2004 pro-forma revenues of approx. € 1.5 billion.

The purchase price for 100 % of the HELIOS shares is € 1.5 billion plus € 100 million for the net cash position. Fresenius will acquire 94 % of the HELIOS shares, 6 % will continue to be held by the HELIOS management.

The acquisition requires antitrust approval. Fresenius anticipates to close this transaction at the end of 2005.

Acquisition of the business of Clinico GmbH – Fresenius Kabi strengthens product portfolio and production network of medical devices
Fresenius Kabi has entered into an agreement to acquire the business of Clinico GmbH, Bad Hersfeld, Germany. Clinico manufactures medical devices used for the application of infusion therapies and clinical nutrition, such as sterile disposables for the application of drugs, application systems for clinical nutrition as well as catheter systems. The company has a development center and a tool-making site in Germany as well as production plants in Poland and China with state-of-the-art production technologies. All Clinico production plants are certified according to ISO and meet the requirements of the FDA.

Fresenius Kabi is the European leader in infusion therapy and clinical nutrition and offers medical devices for the application of these therapies. With the acquisition of Clinico, Fresenius Kabi extends its product portfolio and will distribute Clinico's products through its existing sales and distribution organization. In addition, the company increases its development and production network for medical devices.

Preliminary sales for the fiscal year 2004/05 (September 30) were about € 51 million, mainly achieved with industrial clients. Clinico has over 1,500 employees.

The acquisition requires the approval of the German antitrust authority.

Committed financing
It is planned to finance the acquisitions through a capital increase in the amount of around € 800 million and a bond in the amount of around € 700 million. The capital increase from approved capital is planned to be completed in 2005 with a subscription right granted to shareholders. A major German bank has committed to underwrite the total amount of the capital increase at customary market conditions. The details of the capital increase will be published in the coming weeks. Commitments for a € 700 million bridge financing have been received from two international banks, as the bond is planned to be issued in the first half of 2006. The Else Kröner-Fresenius-Foundation has notified us, that it will participate in the planned capital increase with an amount of € 100 million. In addition, the proceeds from the disposal of unused subscription rights will be fully invested. Allianz Lebensversicherungs-AG has notified us, that it will positively support the planned capital increase.

Fresenius expects the 2005 acquisitions of Labesfal, Clinico and HELIOS to be slightly accretive to 2006 earnings per share and to be clearly accretive as from 2007.

The financing mix of equity and debt is designed to keep Fresenius Group's key credit ratios substantially unchanged.

Excellent financial results in the 1st-3rd quarter 2005 (preliminary); 2005 Group outlook – earnings guidance raised
In context with the announced transactions, Fresenius provides an overview on the financial results of the first nine months 2005.

Based on preliminary figures, Fresenius achieved excellent financial results in the first nine months of 2005.

Group sales increased 7 % in constant currency. At actual rates, sales were € 5,717 million, an increase of 6 %. Earnings increased stronger than sales: Group EBIT rose 13 % in constant currency and 12 % at actual rates to € 702 million. Group net income grew by 28 % in constant currency and 27 % at actual rates to € 159 million.

The business segments made the following contribution to this excellent development:

Based on preliminary figures, Fresenius Medical Care achieved sales growth of 9 % to US$ 5,000 million in the first nine months of 2005. EBIT and net income posted a strong performance: EBIT rose 11 % to US$ 694 million including US$ 8 million of one-time costs related to the transformation of Fresenius Medical Care's legal form into a KGaA. Net income was US$ 338 million, up 15 % from the first nine months of 2004.

For the year 2005, Fresenius Medical Care confirms its outlook and expects a revenue growth at constant currency between 6 and 9 % and a net income growth between 12 and 15 %. The company expects to achieve the upper end of the net income guidance. This guidance does not take into effect the impact of the Renal Care Group acquisition or the one-time costs for the full year 2005 in connection with the transformation of the company's legal form, or the conversion of the preference shares into ordinary shares.

Fresenius Kabi achieved an excellent sales growth of 12 % to € 1,239 million in the first nine months. EBIT increased significantly by 32 % to € 170 million. The EBIT margin was 13.7 % (Q1-3 2004: 11.7 %). In Q3 2005, the EBIT margin improved to 14.3 %.

Fresenius Kabi confirms its full-year EBIT margin outlook of >13.5 %. Constant-currency sales growth is expected at about 10 %.

In the first nine months of 2005, Fresenius ProServe achieved sales of € 552 million, a decrease of 5 % compared to the previous year. On a comparable basis (excluding the nursing home business sold in 2004 and the discontinued international hospital management business), sales would have been on previous year's level. EBIT was € 11 million in the first nine months of 2005 (Q1-Q3 2004: € 3 million; before one-time expenses: € 11 million). Based on a stronger order intake in its project business, Fresenius ProServe expects improved sales and earnings in Q4 2005.

Fresenius ProServe confirms its full-year outlook for 2005 and expects EBIT of € 20 to € 25 million and organic sales growth of 5 to 8%.

Based on these excellent preliminary Group figures, Fresenius raises its full-year earnings outlook (before the announced acquisitions): Net income is expected to grow at >25 % in constant currency. Previously, the Company expected 20 to 25 % net income growth. The projection for constant-currency sales growth remains at 6 to 9 %.

The final figures for the first nine months of 2005 will be announced on November 3, 2005, as originally scheduled.

Key figures of the business segments (preliminary)


Analyst Meeting and live video webcast
Fresenius AG will host an analyst meeting today, Friday, October 14, 2005, at 3.00 p.m. CEDT / 9.00 a.m. EDT at its headquarters in Bad Homburg, Germany.

The live video webcast of the analyst meeting can be followed on this website. A replay of the webcast will be available shortly after the meeting.


Glossary- maximum-care hospitals
The government plan for general and specialty hospitals basically encompasses four categories. Hospitals for maximum-care generally go far beyond the other categories with their range of services. They typically hold their clinical capacities for 24 hours 7days a week and are obliged to particular standards of quality assurance. Furthermore they shall provide state of the art medical and technical equipment. Hospitals for maximum-care are especially obliged to educational and professional training.

• Sales: € 5.7 billion, + 7 % in constant currency, + 6 % at actual rates
• EBIT: € 703 million, + 13 % in constant currency, + 12 % at actual rates
• Net income: € 161 million, + 30 % in constant currency, + 29 % at actual rates
• Fresenius Medical Care continues strong sales and earnings growth
• Fresenius Kabi achieves excellent operating income and strong organic growth
• Fresenius ProServe increases order intake by 20 %

Compared to the preliminary figures announced on October 14, 2005, EBIT improved by € 1 million to € 703 million and net income by € 2 million to € 161 million.

2005 Group outlook confirmed
Fresenius confirms its increased earnings guidance as announced in the preliminary nine-month results release on October 14, 2005 as well as its sales expectation for the full-year 2005 (before the announced acquisitions).

Sales – high organic growth
In the first nine months of 2005, Group sales increased 7 % in constant currency. Organic growth contributed 6 % and acquisitions 2 % to this increase. Currency translation had a -1 % and divestments a -1 % effect on sales. Sales were € 5,712 million, an increase of 6 % at actual rates (Q1-3 2004: € 5,399 million).

Remarkable constant-currency sales growth was achieved in the main markets North America and Europe of 7 % each. Strong growth rates were achieved in Latin America (+20 %) and in Africa (+29 %). In Asia-Pacific, Fresenius Kabi achieved excellent sales growth. The lower project volume at Fresenius ProServe impacted the sales development in this region.



Sales contribution of the three business segments:



Excellent earnings growth
EBITDA increased 11 % in constant currency and 9 % at actual rates to € 937 million (Q1-3 2004: € 857 million). Group EBIT rose 13 % in constant currency and 12 % at actual rates to € 703 million (Q1-3 2004: € 628 million). The Group EBIT margin further improved to 12.3 % in the first nine months of 2005 (Q1-3 2004: 11.6 %).

Group net interest was € -146 million in the first nine months of 2005 (Q1-3 2004: € -156 million). This improvement was mainly the result of a lower debt level compared to the first nine months of 2004 in combination with lower interest rates. The tax rate for the first nine months of 2005 was 39.3% (Q1-3 2004: 40.3 %), in line with the full-year expectation.

Minority interest increased to € 177 million (Q1-3 2004: € 157 million). 96 % was attributable to minority interest of Fresenius Medical Care. Group net income grew strongly by 30 % in constant currency and by 29 % at actual rates to € 161 million (Q1-3 2004: € 125 million). Excellent operating results of the two largest business segments Fresenius Medical Care and Fresenius Kabi, lower interest expenses and a lower tax rate contributed to this increase.

Earnings per ordinary share were € 3.92 (Q1-3 2004: € 3.04). Earnings per preference share were € 3.94 (Q1-3 2004: € 3.06). EPS increased 29 % for both share classes.

Investments considerably increased
In the first nine months of 2005, Group investments increased considerably to € 460 million (Q1-3 2004: € 253 million). € 196 million was spent for property, plant and equipment and intangible assets (Q1-3 2004: € 174 million) and € 264 million for acquisitions (Q1-3 2004: € 79 million). The increase in acquisition spending was mainly driven by Fresenius Kabi.

Solid cash flow performance
Fresenius achieved a very good operating cash flow of € 592 million in the first nine month of 2005 (Q1-3 2004: € 580 million). This positive performance was driven by improved earnings whereas higher income tax payments of Fresenius Medical Care in North America had a negative effect. Free cash flow before acquisitions and dividends was € 412 million (Q1-3 2004: € 423 million). Free cash flow after acquisitions (€ 213 million) and dividends (€ 132 million) was € 67 million (Q1-3 2004: € 232 million). This figure was driven by significantly higher acquisition- spending and higher dividend payments.

Solid balance sheet structure
Total assets increased 12% to € 9,196 million (December 31, 2004: € 8,188 million). In constant currency, total assets grew 5 %. Current assets increased 15 % to € 3,163 million (December 31, 2004: € 2,755 million). In constant currency, current assets grew 9 %. This increase was driven by acquisitions and growth of operations.

Group debt rose 3 % to € 2,821 million as of September 30, 2005 (December 31, 2004: € 2,735 million). In constant currency, debt was 1 % below previous year-end's figure. The net debt/EBITDA ratio was 2.1 as of September 30, 2005 (December 31, 2004: 2.2).

Shareholders' equity including minority interest rose 17 % to € 3,932 million compared to € 3,347 million on December 31, 2004 (at constant currency: +6 %). The equity ratio including minority interest improved to 42.8 % due to strong increase in earnings and currency translation effects (December 31, 2004: 40.9 %).

Employee numbers continue to grow
As of September 30, 2005, the Group had 72,484 employees worldwide, an increase of 6 % (December 31, 2004: 68,494).

Fresenius Biotech
Fresenius Biotech develops innovative therapies with trifunctional antibodies for the treatment of cancer as well as cell therapies for the treatment of the immune system. In the field of polyclonal antibodies, Fresenius Biotech has successfully marketed ATG-Fresenius S for many years. ATG-Fresenius S is an immunosuppressive agent used to prevent and treat graft rejection following organ transplantation.

In the field of trifunctional antibody therapies, the current studies for ovarian cancer (Phase IIa), malignant ascites (Phase II/III) and malignant pleural effusion (Phase I) are continuing according to plan. Results of those studies will be presented for ovarian cancer in the first half of 2006 and for malignant ascites as well as malignant pleural effusion in the second half of 2006. Two phase II studies are in preparation to investigate the treatment of gastric cancer and breast cancer following positive results from two phase I studies for the treatment of peritoneal carcinomatosis and breast cancer. In addition, Fresenius Biotech acquired from its partner Trion the exclusive worldwide clinical development, registration, marketing and sales rights for the trifunctional antibody lymphomun. With this antibody Fresenius Biotech extends its range of indications from solid tumors to malignancies of the blood. The antibody is in preclinical development.

The Business Segments

Fresenius Medical Care
Fresenius Medical Care is the world's leading provider of products and services for patients with chronic kidney failure. As of September 30, 2005, Fresenius Medical Care was serving approximately 130,400 patients (+6 %) in 1,670 dialysis clinics (+5 %). The company delivered about 14.7 million treatments in the first nine months of 2005 (+5 %).

• Strong sales and earnings growth continued
• Excellent performance in North America and Europe
• 2005 outlook confirmed

In the first nine months of 2005, Fresenius Medical Care achieved sales growth of 9 % to US$ 4,999 million (Q1-3 2004: US$ 4,588 million). In constant currency, sales rose 8 %. Organic growth was 7 %.

In North America Fresenius Medical Care achieved a strong sales increase of 7 % to US$ 3,383 million (Q1-3 2004: US$ 3,149 million). Sales outside North America ("International") showed an even stronger growth of 12 % to US$ 1,616 million (Q1-3 2004: US$ 1,439 million). Sales in dialysis care increased 8 % to US$ 3,610 million (Q1-3 2004: US$ 3,334 million). In dialysis products, Fresenius Medical Care achieved sales growth of 11 % to US$ 1,389 million (Q1-3 2004: US$ 1,254 million).

EBIT rose 11 % to US$ 695 million (Q1-3 2004: US$ 625 million) and the EBIT margin was 13.9 % (Q1-3 2004: 13.6 %). EBIT includes one-time costs of US$ 8 million related to the transformation of Fresenius Medical Care's legal form into a KGaA. As previously announced, the company expects one-time costs for the full year 2005 to be approximately US$ 10 million for the transformation. Net income grew by 16 % to US$ 339 million in the first nine months of 2005.

For the year 2005, Fresenius Medical Care reconfirms its outlook. This guidance does not take into effect the impact of the Renal Care Group acquisition or the one-time costs for the full year 2005 in connection with the transformation of the company's legal form, nor the conversion of the preference shares into ordinary shares. For further information, please see Fresenius Medical Care's Investor News at www.fmc-ag.com.

Fresenius Kabi
Fresenius Kabi offers infusion therapies and clinical nutrition for seriously and chronically ill patients in the hospital and out-patient environments. The company is also a leading provider of transfusion technology products.

• New record EBIT margin of 14.3 % in the third quarter of 2005
• Excellent organic growth of 7 % in the first nine months of 2005
• 2005 outlook confirmed

In the first nine months of 2005, Fresenius Kabi's sales rose 12 % to € 1,239 million (Q1-3 2004: € 1,105 million). The company achieved an excellent organic growth of 7 %. Acquisitions, primarily the generic I.V. drug company Labesfal, contributed 5 % to sales. Currency translation added 1 % to sales growth. Divestments had a -1 % effect on sales.

Sales in Germany rose 2 %. Sales in Europe (excluding Germany) increased 14 %. Acquisitions contributed significantly to this growth. Fresenius Kabi continued to grow at double-digit rates outside of Europe: In Asia-Pacific Fresenius Kabi achieved strong growth of 15 %, in Latin America of 20 % and in Africa of 18 %.

EBIT of Fresenius Kabi significantly increased by 32 % in the first nine months to € 170 million (Q1-3 2004: € 129 million). The EBIT margin was 13.7 % (Q1-3 2004: 11.7 %). In Q3 2005, the EBIT margin improved by 50 basis points to 14.3 % compared to Q2 2005. Fresenius Kabi confirms its full-year 2005 outlook.

Fresenius ProServe
Fresenius ProServe offers services for the international health care sector including hospital management and hospital planning and construction as well as planning and construction of pharmaceutical and medical-technical production sites.

• Order intake increased by 20 % in the first nine months of 2005
• Strong 4th quarter in project business expected
• 2005 outlook confirmed

In the first nine months of 2005, Fresenius ProServe achieved sales of € 551 million (Q1-3 2004: € 581 million). On a comparable basis (excluding the nursing home business sold in 2004 and the discontinued international hospital management business), sales were at previous year's level. Sales growth of 2 % to € 260 million was achieved in the hospital management business (Wittgensteiner Kliniken). In the hospital engineering and services business (VAMED) sales rose by 1 % to € 236 million. In the pharmaceutical engineering and services business (Pharmaplan) the order intake improved and Pharmaplan's sales increased in the third quarter 2005.

EBIT was € 11 million in the first nine months of 2005 (Q1-3 2004: € 3 million; before one-time expenses: € 11 million) and in line with the company's expectations.

Order intake and order backlog developed very positively: Order intake in the first nine months of 2005 increased 20 % to € 239 million (Q1-3 2004: € 199 million). Order backlog as of September 30, 2005 rose 19 % to € 399 million (December 31, 2004: € 335 million). Fresenius ProServe expects a strong fourth quarter 2005 in its project business. Fresenius ProServe confirms its full-year outlook for 2005.

Live video webcast
As part of the earnings announcement for the first nine months of 2005, an analyst conference will be held at the Fresenius headquarters in Bad Homburg on November 3, 2005 at 1:30 p.m. CET (7.30 a.m. EST). All investors are cordially invited to follow the conference in a live broadcast over the Internet on this site at Investor Relations / Presentations. Following the meeting, a recording of the conference will be available as video-on-demand.

The Fresenius Health Care Group will expand its biotechnology activities within Fresenius Biotech GmbH, founded in 2003. Fresenius Biotech will concentrate on innovative antibody and cell therapies to fight life-threatening diseases for which no adequate treatment has been found. Dr. Ulf M. Schneider, Chairman of the Management Board of Fresenius AG, commented during the Capital Market Day at the Group's headquarters in Bad Homburg, Germany, where the company detailed the strategy and key projects of Fresenius Biotech.

Dr. Schneider: "Fresenius Biotech is a biotechnology company with a clearly defined strategy benefiting from the know-how and structure of the Fresenius Group. Years of experience in the antibody arena, an experienced management team, an efficient structure and competent partners are the key components to Fresenius Biotech's success."

Fresenius Biotech develops innovative antibody-therapies for the treatment of cancer and cell therapies for the treatment of end-stage HIV infection as well as for the treatment of the long-term rejection prevention of transplanted organs. Fresenius Biotech already offers ATG-Fresenius S, a biotechnological immunosuppressive product that has established itself over many years for acute use in connection with organ transplant operations.
Fresenius Biotech focuses on the clinical development, production, regulatory approval and marketing of biopharmaceuticals. For fundamental research, Fresenius Biotech cooperates with young biotechnology firms, universities and research centers. When necessary, additional alliances and partnerships can win Fresenius Biotech added know-how and marketing assistance.

Fresenius presented the first successful results of a Phase I/II study using the trifunctional antibody removab® for the treatment of ascites in ovarian cancer in September, 2003. Further studies with this antibody are expected to begin this year. Market launch is seen in 2007.

The following is a short overview of Fresenius Biotech's important projects:

I. Antibodies

Trifunctional Antibodies, removab® and rexomun™
Removab® and rexomun™ belong to a new generation of antibodies. These antibodies are called trifunctional because they bind to cancer cells and also to two different cells of the immune system, T-cells and macrophages. Through the creation of this cell complex, the trifunctional antibodies initiate an especially efficient eradication of tumor cells. The goal is to eliminate those tumor cells that may still be present in the body – for example following surgical resection of a tumor – to prevent relapse or the development of metastases. Fresenius in September successfully completed a Phase I/II study of the treatment of ascites in ovarian cancer using the trifunctional antibody removab®. The antibody was shown to be well tolerated and demonstrated the first significant indications of efficacy.

The following additional studies with removab® and rexomun™ have already begun or are expected to begin in the near future:

• A phase II/III study investigating the use of removab® as a therapy against ascites in other malignancies (for example -- stomach cancer or pancreatic cancer) should begin in the 3rd quarter of 2004 and be complete by the 2nd half of 2006. If the results of the study are positive, a launch of the antibody for these indications is planned at the end of 2007.
• Two phase I studies investigating the use of rexomun™ in breast cancer and removab® in peritoneal cancer have already begun.
• A phase I study using removab® in non-small-cell lung cancer has also already begun.
• A phase I/II study using removab® in the treatment of malignant pleural effusion and a phase IIa study using removab® in the treatment of ovarian cancer should begin shortly.

The trifunctional antibodies were developed by the Munich Biotech Company TRION Pharma, a partner of Fresenius Biotech.

Polyclonal Antibodies, ATG-Fresenius S
ATG-Fresenius S is an immunosuppressive therapy made of polyclonal antibodies that has been used successfully for years. Following organ and bone marrow transplants, the protein material suppresses rejection reactions. ATG-Fresenius S has proved itself very effective in various clinical studies and in daily use. Demand for ATG-Fresenius S has continually grown in past years. In 2004, Fresenius Biotech expects a sales increase to about € 16 million (2002: € 15 million). In June, Fresenius Biotech signed an agreement with the U.S. company Enzon Pharmaceuticals, giving Enzon exclusive marketing rights in North America and requiring it to perform the necessary studies for regulatory approval. Fresenius will supply ATG and receive milestone as well as licensing payments. The start of clinical studies in the U.S. is set for mid-2004, with the first sales in the U.S. market expected in 2007.

An ongoing phase III study in Europe, which will be complete in 2008, should also show the efficacy of ATG-Fresenius S in stem cell transplants. Fresenius Biotech expects regulatory approval for these indications, which would present additional growth opportunities for ATG-Fresenius S, in 2009.


II. Cell therapies

Genetically modified T-helper cells for the treatment of HIV
T-helper cells play a central role in the immune system. In an HIV infection, the virus attacks and kills T-helper cells, reducing their numbers in blood over the years. This results in a weakened immune system, eventually leading to an outbreak of AIDS. The goal of Fresenius Biotech is to develop a gene therapy together with external partners that regenerates the immune system of patients. Researchers have genetically modified T-helper cells so that they can no longer be infiltrated by the virus because a protein on the surface prohibits the fusion of the virus and the cell membrane. Preliminary results from a phase I/II study should show by the middle of 2004 whether the treatment concept is effective in humans. The study should be complete in 2005. T-helper cells are taken from the patients, genetically modified and then returned via infusion. The researchers hope the genetically protected cells fortify the body, strengthen the immune system and lengthen or prohibit the outbreak of AIDS. This gene therapy is expected to be used first in patients where the AIDS combination therapy HAART (highly active antiretroviral therapy) wasn't effective. In Europe, between 6,000 and 13,000 patients have failed the HAART regimen.

TAIC: Transplant Acceptance Inducing Cells
Recipients of donor organs must take immunosuppressive medications with strong side effects for their entire life so that their body doesn't reject the foreign organ. In animal experiments with rats the rejection of transplanted organs could be prevented by introducing specially prepared cells from the donor animal to the recipient prior to the transplant.
Blood cells from the donor animals were specifically isolated and, by means of a special laboratory treatment, converted into TAIC (Transplant Acceptance Inducing Cell) and multiplied. The researchers then injected the cells into animals that received an organ transplant days later.
With the TAIC treatment, the probability of rejection, even 150 days after the operation, was under 10 %. In a further study using TAIC, pigs received an organ transplant. One year after discontinuing the immunosuppressive medication the animals survived with a probability of 75 %. All of the pigs and rats not treated with TAIC in the control group rejected the organs in a short period of time. Similar results were found in control groups in which TAIC and donor organs originated from different animals.

The goal of Fresenius Biotech is to develop a therapy for humans together with external partners that enables the long-term acceptance of donor organs by recipients with little or no medication. A pilot study with 10 patients has already begun.


Glossary:
Study phases
The goal of a phase I study is to determine possible dosages and side effects while a phase II study verifies the efficacy and tolerance of a medication using a small number of patients. In addition, the new medication is compared to standard therapies and a benefit-risk analysis is performed.


Fresenius Biotech GmbH is a company of the Fresenius Group, focused on the development and marketing of biopharmaceuticals in the fields of oncology, immunology and regenerative medicine.


Fresenius is an internationally operating Health Care Group with products and services for dialysis, hospitals and the ambulatory medical care of patients. Sales amounted to 5,25 billion euros in the nine months of 2003. On 30 September 2003 the Fresenius Group had 65,941 employees worldwide.

Summary Full Year 2003:
Company met or exceeded financial targets for 2003 and will propose 7th consecutive dividend increase

• Net Revenues: $ 5,528 million, + 9%
• Operating income (EBIT): $ 757 million, + 9%
• Net income: $ 331 million, + 14%
• Operating Cash Flow: $ 754 million, + 37%
• Free Cash Flow: $ 478 million, + 37%
• Dividend Proposal
  (Ordinary Share) € 1.02, + 8%
  (Preference Share) € 1.08, + 8%

Fresenius Medical Care AG (Frankfurt Stock Exchange: FME, FME3) (NYSE: FMS, FMS-p), the world's largest provider of Dialysis Products and Services, today announced the results for the fourth quarter and the full year of 2003.

Ben Lipps, Chief Executive Officer of Fresenius Medical Care, commented: "We have accomplished or even slightly exceeded our targets for 2003. Our results for the year 2003 improved in key financial metrics and showed a strong performance of our operations. We achieved another record operating and free cash flow for 2003 and we are confident that our global strategy is on the right track. We ended the year with a strong momentum, which we believe is a good foundation to look optimistically toward 2004 and beyond."


OPERATIONS

Fourth Quarter 2003:
Fresenius Medical Care AG reports a 15% increase in net income to $ 94.5 million for the fourth quarter 2003

Total revenue for the fourth quarter 2003 increased 7% (+2% at constant currency) to $ 1,452 million. Dialysis Care revenue grew by 7% to $ 1,038 million (+4% at constant currency) in the fourth quarter of 2003. Dialysis Product revenue (including internal sales) increased by 13% to $ 551 million (+3% at constant currency) in the same period. The internal sales increased to $ 136 million after $ 105 million in the fourth quarter of 2002.

North America:
Revenue rose 1% to $ 993 million, compared to $ 979 million in the same period last year. Dialysis Care revenue in the US increased by 3% to $ 887 million. Same store treatment growth improved again in the fourth quarter to 4.1%. Excluding Puerto Rico the North American same store treatment growth was 4.3% in the fourth quarter of 2003. The average revenue per treatment was at $ 280 in the fourth quarter of 2003 (Q3 2003: $ 279). North American Dialysis Product revenue, including sales to company-owned clinics, increased 5% to $ 207 million.

International:
Revenue was $ 459 million, up 21% (+5% at constant currency). Dialysis Care revenue reached $ 151 million in the fourth quarter 2003, up 34% (+15% at constant currency). Same store treatment growth in the fourth quarter was very strong at 7%. Dialysis Products revenue, including sales to company-owned dialysis clinics, increased 18% to $ 345 million (3% at constant currency).

Operating Income (EBIT) increased 13% to $ 208 million resulting in an operating margin of 14.3% (Q4 2002: 13.6%). The increase of 70 basis points was mainly due to increased treatments and efficiency improvements in North America and reimbursement increases in Italy, Portugal and Venezuela but partially offset by the impacts from the changes in the distribution network in Asia-Pacific and increased cost of revenue due to the strengthening of the Euro. Sequentially, in the fourth quarter the margin in North America increased by 60 basis points to 14.6%. In our International segment it increased by 30 basis points to 15.8% compared to the prior quarter.

Earnings per share (EPS) in the fourth quarter 2003 rose 15% to $ 0.98 per ordinary share ($ 0.33 per ADS), compared to $ 0.85 ($ 0.28 per ADS) in the fourth quarter of 2002. The weighted average number of shares outstanding during the fourth quarter of 2003 was approximately 96.2 million.

In the fourth quarter of 2003, the Company generated $ 251 million in cash from operations. The company benefited from the roll-over of certain hedged inter-company financing transactions in the amount of $ 104 million in the fourth quarter of 2003. A total of $ 147 million (net of disposals) was spent for capital expenditures. The capital expenditures were higher in the fourth quarter since the company used the high operating cash flow as an opportunity for an early lease buyout refinancing of $ 66 million for the Ogden production plant in North America. Including this re-financing transaction the Free Cash Flow before acquisitions for the fourth quarter 2003 was $ 104 million compared to fourth quarter of 2002 with $ 110 million. A total of $ 13 million in cash was spent for acquisitions. Free Cash Flow after acquisitions was $ 91 million compared to $ 103 million in the fourth quarter of 2002.

Full Year 2003:
For a complete overview of the full year 2003 please refer to the appendix.

For the full year 2003, net income was $ 331 million, up 14% from the same period in 2002.

In accordance with the US-GAAP Accounting Standard SFAS 145, the loss from the early redemption of the Trust Preferred Securities in the first quarter of 2002 of $ 12 million after taxes ($ 20 million before taxes) had to be reclassified from extraordinary loss to interest expense and income tax expense. Excluding the redemption loss, net income for the full year of 2002 was $ 302 million. Net revenue was $ 5,528 million, up 9% from the full year 2002. Currency adjusted, net revenue rose 5% in 2003 compared to 2002. Operating Income (EBIT) increased 9% to $ 757 million resulting in an operating margin of 13.7%. For the full year 2003, earnings per ordinary share rose 14% to $ 3.42. Earnings per ordinary ADS for the full year 2003 were $ 1.14.

Cash from operations during the full year 2003 was up 37% or $ 754 million compared to $ 550 million in the year 2002. A total of $ 276 million was spent for capital expenditures (net of disposals) resulting in a Free Cash Flow before acquisitions for the full year 2003 of $ 478 million, an increase of 37% compared to $ 349 million for the full year 2002. This exceptional Cash Flow performance was driven by strong improvements in working capital management. The company reduced the days sales outstanding (DSO) by 7 days to 89 days in 2003, with strong contributions from North America as well as the International region. In addition, cash flow for the fiscal year 2003 benefited from the roll-over of certain hedged inter-company financing transactions in the amount of $ 132 million. Net cash used for acquisitions was $ 92 million. Free Cash Flow after acquisitions increased therefore 43% to $ 386 million.

As of December 31, 2003, the Company operated a total of 1,560 clinics worldwide (1,110 clinics/+3% in North America and 450 clinics/+13% International).

Fresenius Medical Care AG performed approximately 17.8 million treatments, which represents an increase of 9% year over year. North America accounted for 12.4 million treatments (+6%) and the International segment for 5.5 million (+15%).

At the end of the fourth quarter 2003, Fresenius Medical Care served about 119,250 patients worldwide which represents an increase of 6%. North America cared for ~82,400 patients (+3%) and the International segment for ~36,850 patients (+13%).

Dividends
The Company will continue to follow an earnings-driven dividend policy. For the seventh consecutive year, shareholders can expect an increased dividend for the fiscal year 2003. At the Annual General Meeting on May 27, 2004 shareholders will be asked to approve a dividend of € 1.02 per ordinary share (2002: € 0.94) and € 1.08 per preference share (2002: € 1.00). This is an increase of 8% compared to 2002.

Management Board
Ben Lipps was reconfirmed as Chairman of the Management Board and Chief Executive Officer of Fresenius Medical Care AG.

Rainer Runte, who joined the Management Board in 2002 as a deputy member, has been appointed to be a full member of the Management Board responsible for Law and Compliance worldwide. In addition, Rice Powell and Mats Wahlstrom have been appointed as new board members of the Company's Management Board. Both will be responsible for North America. All appointments are effective as of January 1st, 2004.

Rice Powell, age 48, has more than 25 years of experience in the healthcare industry. Since 1997 Rice Powell has been the President of Renal Products division of Fresenius Medical Care in North America including the Extracorporal Therapy and Laboratory Services.

Mats Wahlstrom, age 49, also has nearly 20 years of experience in the renal field. Since November 2002 Mats Wahlstrom has been the President of Fresenius Medical Care's Medical Services division in North America.

Ben Lipps, Chief Executive Officer of Fresenius Medical Care, commented: "I am pleased with the breadth and experience of our management board with more than 120 years of combined renal experience. Mats and Rice also bring significant renal experience and a history of accomplishments and I whole heartedly welcome them to the Management Board. Clearly we intend to achieve our strategic initiatives and objectives to ensure stakeholder value".

OUTLOOK 2004
For the year 2004, the Company expects revenue growth at constant currencies in the mid-single digit and net income growth in the high-single digit to low-double digit range. In 2004 the company expects capital expenditures of about $ 250 million and spending on acquisitions of about $ 100 million.

Fresenius announces that its Supervisory Board unanimously appointed with immediate effect Dr. Ben Lipps a member of the Management Board of Fresenius AG in its March 16, 2004 meeting. Dr. Lipps will continue in his role as Chairman of the Management Board and CEO of Fresenius Medical Care AG.

"Ben Lipps has built our dialysis business in the United States from small beginnings to a key Fresenius revenue and earnings contributor", commented Dr. Ulf M. Schneider, Chairman of the Management Board of Fresenius AG. "With his energy, his exceptional dedication and more than 35 years experience in dialysis Ben Lipps will continue to expand Fresenius Medical Care's leadership position. I am very pleased that he will also bring his extensive experience and strategic initiatives to the Management Board of Fresenius AG."

Dr. Lipps joined Fresenius USA in 1985 and held several senior executive positions with the company. He has been a member of the Management Board of Fresenius Medical Care since the company was founded in 1996 and was appointed Chairman in 1999.

The Management Board of Fresenius AG now includes the following members:

• Dr. Ulf M. Schneider, Chairman
• Rainer Baule, CEO Fresenius Kabi
• Rainer Hohmann, CEO Fresenius ProServe
• Dr. Ben Lipps, CEO Fresenius Medical Care
• Udo Werlé, CFO and Labor Relations Director